source
- FDA approves first mRNA seasonal flu vaccine, mFlusiva, a year after funding cutsThe U.S. Food and Drug Administration granted approval to mFlusiva, the first mRNA‑based seasonal influenza vaccine, after its advisory committee voted unanimously that the benefits outweigh the ri…
- Study uncovers tau’s role in reversing mitochondrial electron flow, offering new Alzheimer’s drug targetA Stanford-led research team has identified a previously unknown way that the protein tau disrupts cellular function, adding to its status as a leading target in Alzheimer’s drug development. The…